Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Clinical trial NCT04095858 · TERMINATED
Trial details
- NCT number
- NCT04095858
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-05
- Primary completion
- 2021-11-05
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.